Get Adobe Flash player


AuthorsT. L. Arkhypkina, L. P. Lyubimovа, O. V. Tyazhelova, N. A. Kravchun

Pages: 161–168


Polycystic ovary syndrome (РCOS) is one of the most studied pathologies in gynecology, and despite this, its etiology and pathogenesis is not completely understood. Lately, more attention has been paid to study the role of endothelial dysfunction as one of the causes of PCOS.

Objective. Estimate the level of endothelin-1 (as a marker of endothelial dysfunction) in the blood and its relationship with hormonal and metabolic parameters at young women with PCOS.

Methods. We examined 40 patients (age 21.4 ± 0.2 years) with PCOS. All patients have different complaint: for primary infertility – 100%, for menstrual dysfunction in the form of oligomenorrhea – 30 (75%), secondary amenorrhea – 7 (17.5%), hirsutism – 32 (85%), acne – 16 (40%), adiposity – 15 (37.5%). The control group: 15 healthy women with a normal menstrual function, who want to determine the state of the reproductive system before planning of pregnancy.

Results. During the study of the marker of activity endothelial function, there was found that the basal levels of ET-1 in the serum of young women with PCOS (2.29  ±  0,2 fmol/ml) were significantly higher than of the healthy women (0,83 ± 0,2 fmol/ml; p > 0.05). To the frequency of determine of increase ET-1 found that 21 (84%) patients of the first group value of ET-1 in 1.5 times, and in 12 (80%) patients in the second group 2.8 times higher than the healthy women.

Conclusions. It was found that patients with PCOS have increased level of endothelin-1 regardless of body weight and presence or absence metabolic disorders. A positive correlation between levels of endothelin-1 and LH, T/E2 coefficient and a negative correlation with level of E2 was established. Determination of plasma concentrations of endothelin-1 may be useful to identify factors activating endothelial system, but its increase cannot be considered as an independent diagnostic marker for PCOS.

Keywords: polycystic ovary syndrome, metabolic syndrome, endothelin-1.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text


  1. Gamazov OA. [Еndothelium – "endocrine tree"]. Nature. 2000;(5):38–46.
  2. Malaya LT, Korzh AN, Balkova LB. Endothelialnaya disfunciya pri pathologii serdechno-sosudistoi sistemy [Endothelial dysfunction in pathology of the cardiovascular system ]. Kharkiv: Torsing, 2000. 432 р.
  3. Popov EV. [Endothelins: origin, physiological effects and possible role in the pathology]. Tuberculosis and Lung Disease. 2010;87(5):3–13.
  4. Rubanyi GM, Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev. 1994;(46):325–415.
  5. Yanagisawa M , Kurihara H, Setel K. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature.1988;332:411–415.
  6. Maguire JJ, Kuc RE, Davenport AP. Orphan – receptor ligand human urotensim II : receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol. 2000;131:441–446.
  7. Inoue A, Yanagisawa M, Kimura S. Human endothelin family: three structurally and pharmacologically distinet isopeptides predicted by three separate genes. Proc. Nat. Acad. Sci. 1989;86:2863–2867.
  8. RubanyiGM. Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev.1994;(46):325–415.
  9. Webb DJ. Endothelin: from molecule to men. Br. J. Clin. Pharmacol.1997;44:9–20.  
  10. Shah R. Endothelins in health and disease. Eur. J. Internal. Med.2007;18:271–282.
  11. Giaid A, Polak JM, Gaitonde V. Distribution of endothelin – like immunoreactivity and mRNA in the developing and adult human lung. Am.1991;(4):50–58.
  12. Lisa K, Wedgwood S, Steinhorn RH, Black SM. Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. Am. J. Physiol. – Lung Cell Med. Physiol.2004;286(5):984–991.
  13. Yoshimoto S, Ishizaki Y, Sasaki T, Mutora S. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke.1991;(22):378–83.
  14. Korzh A. [Current concepts about the structure, function and biological role of the vascular endothelium]. Internal J. Med. 2003;(1):130–134/
  15. Lupinskaya PA. [Vascular endothelium – the main regulator of local blood flow]. Vestnik KRSU. 2003;(4):3–12.
  16. Kolomoets NM. [Endothelial dysfunction and its clinical significance]. Military Med. J. 2001;(5):29–35.
  17. Kurshakov A, Saifutdinov R., Anchikova L. [Insulin resistance and endothelial dysfunction in metabolic syndrome]. Kazan Med. J. 2011;92(2):173–176.
  18. Kravchun PG. [Endothelial function and cardiac hemodynamics in clusters separated by the level of endothelin-1 in acute myocardial infarction and late postinfarction period]. Internal. J. Med. 2012;(1):22–27.
  19. Kravchun NO. Osobluvosti formyvannya sercevo-cydunnuh uskladnen cykrovogo diabety 2 tupy y hvoruh z riznumu proyavamu metabolichnogo sundromy [Features of formation of cardiovascular complications of type 2 diabetes in patients with various manifestations of metabolic syndrome and their pharmacological correction]: dis ... Dr. med. Sciences: 14.01.14, protected. 10.05.07 08.11.07. -
  20. Diamanti-Kandarakis E, Spina G, Konli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metabol. 2001;86(10):466–467.
  21. Dedov II, Butrova SA. [Polycystic ovary syndrome and metabolic syndrome]. Obes. Metab. 2006;(1):31–33.
  22. Turk J. Endothelial dysfunction and insulin resistance in young women with polycystic ovarian syndrome. Med. Sci. 2014;44:787–791.
  23. Taslipinar Y, Kilic N, Bayraktar M. Vascular risc in young women with polycystic ovary and polycystic ovary syndrome. Gynecology.2008;111(2):385–395.
  24. Mather KJ, Verma S, Corenblum B, Anderson TJ. Normal endothelian function despite insulin resistence in healthy women with the polycystic ovary syndrome. J. Clin. 2000;85:1851–1856.
  25. Tepleshina EA [The role of endothelin and vascular endothelial growth factor in the process of folliculogenesis]. Russ. vestnik obstet. gynecol. 2011;(3):4–8.
  26. Kao YH, Chin WC, Hsu MI, Chen YJ. Endothelial Progenitor Cell Dysfunction in Polycystic Ovary Syndrome: Implications for the genesis Cardiovascular Diseases. Int. J. Fertil. Steril. 2013;6(4):2008–2013.
  27. AzzizR, CarminiE, DewaillyCriterial for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society. 2006;9(14237–4245.
  28. Khaodhiar L, Mc CowenKC, Blackburn G.1999;2(1):17–31.
  29. MatthewsDR, HoskerJP, Rudenski. Diabetologia.1985;28(7):412–419.
  30. Dedov II, Melnichenko GA. Sindrom polikistoznux yaichnikov: rukovodstvo dlya vrachei [Polycystic Ovary Syndrome: A Guide for Physicians]. Moscow: Medical informative agency, 2007. 368 p.
  31. Mancini F, Cianciosi A, Reqiani GM. Endothelian function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight cumenorrheic women and PCOS patients : a pilot study. Fertil. Steril. 2009;91(6):2537–2544.
  32. Lim SSR, Norman J, . Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes. Rev .2013;14(2):95–109.
  33. Suxix GT, Biryukova AM, Nazarenko T, Durinyan ER. [Endocrine and metabolic features in patients with polycystic ovary syndrome]. Obstet. Gynecol. 2011;(4):45–49.
  34. Marin P, Holmang S, Jonsson L. The effect of testosterone treatment on body composition and metabolism in middle-aged obese men. International Journal of Obesity and Related Metabolic Disorders.1992;16(12):991
  35. Rizzo M, Rini GB, Carmina E. Androgen excessand cardiovasculary risc. Minerva Endocrinol.2007;32(1):67
  36. Homburg R, Crawford G. The role of AMH in anovulation associated with PCOS: a hypothesis. Hum. Reprod.2014;29(6):1117–1121
  37. Nazarenko TA. Stimulaciya funkcii yaichnikov [Stimulation of ovarian function]. Moscow: MEDpress-Inform, 2008.72 p.
  38. Nardo LG, Gelbaya TA, Wilkinson H, Yater A. Circulating basal anti-Mullerian hormone levels os predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertillity and Sterility.2009;92(5):1586–1593.